Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Percutaneous Closure of an Iatrogenic Intracardiac Shunt in Treating Torrential Tricuspid Regurgitation.

ABSTRACT: A patient presented with severe right heart failure due to a large LV-to-RA shunt with left-to-right shunting and torrential tricuspid regurgitation 6-weeks following surgical sub-aortic stenosis resection. Retrograde delivery of an Occlutech ventricular septal defect device produced instantaneous resolution of shunt, reduction in tricuspid regurgitation, and impressive diuresis of 28 kg.

SUBMITTER: Duncan A

PROVIDER: S-EPMC11190469 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Percutaneous Closure of an Iatrogenic Intracardiac Shunt in Treating Torrential Tricuspid Regurgitation.

Duncan Alison A Weale Jonathan J DeSouza Anthony A Rigby Michael M Heng Ee Ling EL

JACC. Case reports 20240605 13

A patient presented with severe right heart failure due to a large LV-to-RA shunt with left-to-right shunting and torrential tricuspid regurgitation 6-weeks following surgical sub-aortic stenosis resection. Retrograde delivery of an Occlutech ventricular septal defect device produced instantaneous resolution of shunt, reduction in tricuspid regurgitation, and impressive diuresis of 28 kg. ...[more]

PMID: 38912319

Similar Datasets

Treating Recurrent Tricuspid Regurgitation and Iatrogenic Atrial Septal Defect.

Project description:Heterotopic caval valve implantation may be a reasonable option for alleviating symptoms in select high-risk patients with recurrent tricuspid regurgitation after failed interventional tricuspid valve repair. However, altered right atrial hemodynamic status should be considered in procedural planning to avoid potential right-left shunting in cases of septal defects. (Level of Difficulty: Advanced.).

| S-EPMC10119479 | biostudies-literature

Torrential tricuspid regurgitation in Ebstein's anomaly, never seen so clear!

Project description: Not available

| S-EPMC11367949 | biostudies-literature

Transcatheter Repair of Acute Torrential Tricuspid Regurgitation Presenting as Platypnea-Orthodeoxia Syndrome.

Project description:An 82-year-old man developed acute breathlessness and cyanosis, exacerbated while upright and improved on lying flat (platypnea-orthodeoxia syndrome). Echocardiography revealed acute torrential tricuspid regurgitation due to a flail posterior leaflet leading to right-to-left shunting through a patent foramen ovale (PFO). The patient's symptoms resolved after transcatheter PFO closure and tricuspid valve edge-to-edge repair.

| S-EPMC11911849 | biostudies-literature

Iatrogenic interatrial shunt reversal with transcatheter tricuspid valve repair.

Project description: Not available

| S-EPMC9724859 | biostudies-literature

Intracardiac Echocardiography-Guided Percutaneous Aspiration of Tricuspid Vegetations.

Project description: Not available

| S-EPMC11307922 | biostudies-literature

Tailored Treatment of Patients With Intracardiac Leads and Tricuspid Regurgitation.

Project description:Tricuspid regurgitation (TR) is frequent in patients with leads from rhythm control devices. Percutaneous treatment of TR can be an effective therapy in these patients but needs to be tailored based on valve anatomy and the underlying mechanism of the TR as shown in the case series that we present. (Level of Difficulty: Advanced.).

| S-EPMC10119508 | biostudies-literature

Surgically Assisted Transcatheter Balloon-Expandable Valve in Inferior Vena Cava for Torrential Tricuspid Regurgitation.

Project description: Not available

| S-EPMC6200689 | biostudies-literature

Future Perspectives in Percutaneous Treatment of Tricuspid Regurgitation.

Project description:Tricuspid regurgitation (TR) has a not negligible prevalence and its severity is correlated with poorer outcomes. However, surgical options are rarely offered to these patients because of their high surgical risk. Given that medical therapy plays a limited role in the management of these patients, there is an increasing clinical need for transcatheter treatment options. Although, transcatheter tricuspid valve interventions (TTVIs) are still at an early stage, emerging data suggests their clinical effectiveness and safety, with preliminary results highlighting the potential benefits of transcatheter treatments over medical therapy. In this review, we highlight the challenges and future directions of current and emerging technologies dedicated to the treatment of TR along with an analysis of the next steps required in future clinical trials and studies dedicated to the treatment of the forgotten valve.

| S-EPMC7591745 | biostudies-literature

Unmasking Severe Tricuspid Valve Regurgitation After Percutaneous Debulking of Large Tricuspid Vegetation.

Project description:A 27-year-old man admitted with tricuspid valve endocarditis with a large vegetation, persistent bacteremia, and pulmonary and systemic septic embolization was deemed not a suitable surgical candidate. He underwent percutaneous vegetation debulking using the AngioVac system. The patient defervesced post-operatively with clinical improvement but with abruptly worsened tricuspid regurgitation. (Level of Difficulty: Beginner.).

| S-EPMC8311153 | biostudies-literature

Tricuspid Regurgitation: Disease State and Advances in Percutaneous Therapy.

Project description:Tricuspid regurgitation (TR) is a relatively common finding. There has been growing recognition of the morbidity and adverse prognosis of severe TR, which affects 1.6 million people in the US. However, symptomatic TR remains undertreated despite emerging therapeutic modalities. In this review, the pathophysiological and epidemiological features of TR are examined and the diagnosis, natural history, and clinical presentation are discussed. An overview of TR therapy is provided, including medical and surgical treatments, as well as novel percutaneous approaches. The currently available studies on percutaneous therapy demonstrate promise for transcatheter valve repair and replacement with favourable clinical outcomes and short-term durability. However, further study is needed.

| S-EPMC10583156 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data